Skip to Content
Søg Menu
2.-6. juni 2023

Følg med når vi dækker ASCO 2023 | American Society of Clinical Oncology

Nyheder fra ASCO 2022

The randomized DYNAMIC Trial: ctDNA-guided approach towards adjuvant chemotherapy

  • / Jeanne Tie

David Cella, Dr

HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

/ David Cella
ASCO22Nyrecancer Play the Video

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
ASCO22Brystcancer

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
ASCO22Lymfom

Få seneste nyt fra dit speciale

Tilmeld dig og bliv opdateret, når der er nyt fra dit speciale

Tilmeld mig

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
ASCO22Nyrecancer

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
ASCO22Hudcancer

Gratifying new treatment of advanced Urothelial Cancer

ASCO19

ASCO 2019: Meet the unique needs of older patients with cancer

/ William Dale
ASCO19Cancer Play the Video

ASCO 2019: A new potential de-escalation standard neoadjuvant treatment of HER2-positive breast cancer

/ Theodoros Foukakis
ASCO19Brystcancer Play the Video

ASCO 2019: New standard first-line therapy for EGFR mutant NSCLC

/ Bjørn Henning Grønberg
NSCLCASCO19 Play the Video

ASCO 2019: New promising drug for second-line SCLC patients

/ Bjørn Henning Grønberg
ASCO19Lungecancer Play the Video

ASCO 2019: Flere interessante opfølgende studier af lungecancer

/ Odd Terje Brustugun
ASCO19Lungecancer Play the Video

ASCO 2019: Highlights from ASCO about prostate and kidney cancer

/ Daniel Heinrich
ASCO19ProstatacancerNyrecancer Play the Video

ASCO 2019: Paradigm shift in treatment of metastatic cutaneous squamous cell carcinoma

/ Michael R. Migden
HudcancerASCO19 Play the Video

Potentiel førstelinjebehandling ved avanceret renalcellecarcinom

  • / BestPractice Nordic

NYHED | E-LÆRINGSKURSUS OM IMMUNTERAPI

Immunterapi: Undgå at overse bivirkninger

Tilmeld dig her

Abstracts og artikler fra ASCO 2021

Woman with cancer looking at x-ray

Neoadjuvant nivolumab + kemoterapi forbedrer komplet patologisk responsrate og forkorter operationstid uanset stadie af NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21
Man at the doctor

Radioligand reducerer risikoen for progression og død for patienter med metastatisk kastrationsresistent prostatacancer

/ BestPractice Nordic
ASCO21Prostatacancer
Self Diagnosis Of Early Breast Cancer

Olaparib kan ændre klinisk praksis i adjuverende behandling af brystcancer

/ BestPractice Nordic
BrystcancerASCO21
Tværsnit af en nyre

KEYNOTE-564 viser lovende resultater for adjuverende behandling med pembrolizumab til højrisiko nyrekræft

/ BestPractice Nordic
ASCO21Nyrecancer
Lung Cancer

Bliver atezolizumab ny standard for adjuverende behandling af patienter med NSCLC?

/ BestPractice Nordic
NSCLCLungecancerASCO21
Læge ser på røntgenfotografi af patient

Immunrelaterede bivirkninger ved atezolizumab har sammenhæng med bedre overlevelse for patienter med NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21

Nivolumab plus cabozantinib i 1. linje fordobler PFS ved avanceret renalcellecarcinom – på tværs af subgrupper

/ BestPractice Nordic
ASCO21Nyrecancer

Kombineret immunterapi forbedrer overlevelsen for patienter med NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21

Se tidligere dækning af ASCO 2020

Skandinavisk studie viser lovende resultater for patienter med småcellet lungecancer

/ Peter Meldgaard
ASCO20LungecancerKemoterapi

Targeteret førstelinjebehandling giver opløftende resultater for patienter med ALK-positiv NSCLC

/ Peter Meldgaard
NSCLCASCO20Lungecancer

Overbevisende effekt af osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

/ Peter Meldgaard
NSCLCASCO20Lungecancer

The SPARTAN study – the treatment of non-metastatic castration-resistant prostate cancer

/ Eric J. Small
ASCO20Prostatacancer

CheckMate 9LA – Investigating the role of immunotherapy combinations in patients with non-small cell lung cancer

/ Martin Reck
ASCO20LungecancerImmunterapiKemoterapi

Betydeligt fremskridt for behandling af ikke-metastatisk, kastrationsresistent prostatacancer

/ Andreas Røder / Klaus Brasso
ASCO20Prostatacancer
Mere

Back to top